Oncology

Amgen reveals the price of EVENITY Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD 1,825 a month, the bone-building drug was approved by the FDA recently for the treatment of Osteoporosis in postmenopausal women and now will be available in the U.S. The price of Evenity is 34-74% lower than the cost of other available drugs like Tymlos of Radius Health and Forteo of Eli Lilly. Bardy Diagnostics raises USD 35.5 Million Bardy Diagnostics, an American based leading provider of ambulatory cardiac monitoring technologies has raised USD 35.5 million. The Series B funding was led by River Cit...